TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M

TG THERAPEUTICS, INC.

2025-Q2 EPS reported $0.20 revenue$262,004,000

Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.
Net income $28.2M in Q2 2025 vs $6.9M in Q2 2024; cash and securities $278.9M.
Raises FY 2025 BRIUMVI U.S. net revenue guidance to $570-575M (prior $560M); total global revenue target ~$585M.
R&D expense $31.8M (up from $17.6M) driven by subcutaneous development; SG&A $55.6M (up from $38.8M) for commercialization.
Pipeline: Phase 3 ENHANCE trial for consolidated IV dosing ongoing; Phase 1 azer-cel in autoimmune diseases first patient dosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.